Lin Chun-Ru, Tsai Sung Huang Laurent, Wang Che, Lee Cheng-Lin, Hung Shao-Wen, Ting Yi-Tang, Hung Yu Chiang
Department of Medical Education, Chang Gung Memorial Hospital, Linkou Branch, No. 5, Fuxing Street, Guishan District, Taoyuan City 333, Taiwan.
Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Keelung Branch, No. 222, Maijin Rd., Anle Dist., Keelung City 204006, Taiwan.
Life (Basel). 2023 Oct 14;13(10):2058. doi: 10.3390/life13102058.
This study intends to assess the analgesic effects, physical facilitation, and safety of willow bark use in patients with arthritis. Our study was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. PubMed, Scopus, EMBASE, Web of Science, Cochrane, and ClinicalTrials.gov were searched for relative randomized controlled trials (RCTs) describing the efficacy or adverse events of willow bark in patients with arthritis until 12 April 2023. We used Cochrane ROB 2.0 and the Grading of Recommendations, Assessment, Development, and Evaluations system to evaluate the quality of studies and evidence. The meta-analysis was carried out by the fix-effects model. This study included five studies with six RCTs consisting of 329 patients with arthritis. The results showed significant differences in pain relief and improvement in physical status for patients with arthritis between willow bark treatment and placebo groups, and no significant differences in the risk of all adverse events in patients with arthritis between willow bark treatment and placebo. Owing to the potential bias, the certainty and evidence of our findings are still inadequate. Therefore, further RCTs are needed to confirm our results.
本研究旨在评估柳树皮对关节炎患者的镇痛效果、身体机能促进作用及安全性。我们的研究是根据系统评价和Meta分析的首选报告项目声明进行的。检索了PubMed、Scopus、EMBASE、Web of Science、Cochrane和ClinicalTrials.gov,以查找描述柳树皮对关节炎患者疗效或不良事件的相关随机对照试验(RCT),检索截至2023年4月12日。我们使用Cochrane ROB 2.0和推荐分级、评估、制定与评价系统来评估研究和证据的质量。采用固定效应模型进行Meta分析。本研究纳入了5项研究,其中有6项RCT,共329例关节炎患者。结果显示,柳树皮治疗组与安慰剂组相比,关节炎患者的疼痛缓解和身体状况改善存在显著差异,而柳树皮治疗组与安慰剂组的关节炎患者所有不良事件风险无显著差异。由于存在潜在偏倚,我们研究结果的确定性和证据仍然不足。因此,需要进一步的随机对照试验来证实我们的结果。